AlkaliDx is a privately-held research & development company focused on channelopathy forms of PMDD and ADHD. We are developing a novel diagnostic test, an understanding of the genetics, and improved treatments for these diseases.

Premenstrual syndrome (PMS) affects about half of women, and its especially disabling subset Premenstrual Dysphoric Disorder (PMDD) affects 3-8% of women of reproductive age.  These have major economic and personal costs, including a risk of suicide that is double that of women without PMDD.  Although there are several recommended treatments, all have significant side effects.  Some treatments are drastic, such as removal of ovaries, and all are empirical because the cause of PMS is unknown despite its high heritability. In addition, 7% of US children get prescription drugs for Attention Deficit (Attention Deficit Hyperactivity Disorder or ADHD and Attention Deficit Disorder or ADD), mostly in the form of amphetamines. Such amphetamines have been shown to improve focus, but come with side effects and risks of misuse and abuse.

AlkaliDx discoveries offer an alternative benign therapy for the large subgroup of patients for whom the anesthetic lidocaine does not work (roughly 10 million in the US and 150 million worldwide), that enables patients to use our alternate therapy.

Copyright © 2020 AlkaliDx Inc. All rights reserved.